The results showed that D35LNP activated T cells in vivo for anti-tumor treatment in a CD8 T cell-dependent manner.[37] In 2020, Billingsley et al. reported ionizable lipids (C14–4) as a component of LNP for CAR mRNA delivery to primary human T cells.[38] In 2022, Rurik et al. constructed T cell-targeted LNPs, which were surface-modified with anti-CD5 antibodies and loaded with mRNA encoding fibroblast activation protein (FAP)-CAR. This evidence concerns the gene CD8A and neoplasm.